Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. High grade spontaneous SAH (Fisher Grade III and IV)~2. Secured aneurysm (clipped/coiled)~3. Evidence of severe vasospasm - MCA mean flow velocity \>200 cm/sec and Lindegaard ratio \>6 OR Symptomatic vasospasm with either angiographic evidence (no angioplasty), or at least moderate severity according to TCD criteria (MCA mean flow velocity \>150 cm/sec and Lindegaard ratio \>3, or ACA vasospasm)~4. Age ≥18~Exclusion Criteria:~1. Allergy to local anesthetic or contrast~2. Coagulation disorders with PT \<70%, or INR \>1.4, or PTT \>1.5 times control and/or platelets \<70,000x106/L~3. Use of enoxaparin within 12 hours~4. Use of clopidogrel within 7 days~5. Use of coumadin within 5 days~6. Use of ticlopidine within 14 days~7. Use of intravenous thrombolytics within 10 days~8. Any use of hirudin derivatives during ICU stay

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Block (Type: EXPERIMENTAL): None
- Standard Care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).